<DOC>
	<DOCNO>NCT02663323</DOCNO>
	<brief_summary>MeRes-1 Extend study design prospective , multinational , multicentre , single arm , open label , pilot study assess safety performance MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System ( BRS ) subject de novo native coronary artery lesion . 64 subject enrol 8 center locate Asia Pacific , Europe , Brazil South Africa . Primary outcome study Proportion population report Major Adverse Cardiac Events 6 month day index Procedure .</brief_summary>
	<brief_title>Pilot Clinical Study MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>General 1 . Male female subject ≥ 18 year age 2 . Subject able sign write Informed Consent Form ( ICF ) 3 . Subjects symptomatic myocardial ischemia , chronic stable angina 4 . The patient plan intervention single de novo lesion native epicardial vessel 5 . Subject acceptable candidate Coronary Artery Bypass Grafting ( CABG ) 6 . Subject participate clinical investigation/study agree participate clinical investigation/study period 3 year follow index procedure . 7 . Subject must agree undergo clinical investigation planrequired followup visit , angiogram OCT per protocol . Angiographic 1 . Subject maximum two treatable de novo lesion locate maximum one per native epicardial vessel locate major artery branch , reference vessel diameter 2.75 , 3.00 3.5 mm line QCA . 2 . Target lesion length ≤ 20 mm . 3 . Subjects Lesion ( ) , visually estimate stenosis ≥ 50 % &lt; 100 % TIMI flow ≥ 1 . General 1 . Subjects unable provide write informed consent . 2 . Pregnant nursing mother plan pregnancy clinical investigation ( female patient must negative pregnancy test do within 7 day prior index procedure effective contraceptive must use participation clinical investigation ) . 3 . Subjects know allergy PolyLLactide ( PLLA ) , PolyD , LLactide ( PDLLA ) , Sirolimus ( Rapamycin ) analog derivative , clopidogrel , ticlopidine , prasugrel , contrast medium , platinum , ticagrelor drug dual antiplatelet therapy include aspirin , heparin bivalirudin . 4 . Subject diagnose Acute Myocardial Infarction ( AMI ) within 7 day precede index procedure , indicate elevated level cardiac enzymes and/or ST segment change Electro Cardio Gram ( ECG ) . 5 . Subject history previous revascularization procedure include CABG Percutaneous Coronary Intervention ( PCI ) . 6 . Subject vascular aneurysm , cardiac arrhythmia , congestive cardiac failure LVEF &lt; 30 % , cardiac tamponade . 7 . Recipient organ organ transplant procedure wait list organ transplant . 8 . Subjects receive immunosuppression therapy know immunosuppressive autoimmune disease . 9 . Subjects history stroke , Cerebro Vascular Accident ( CVA ) Transient Ischemic neurological Attack ( TIA ) . Patients renal insufficiency creatinine level 1.3 mg/dl , know aplastic anaemia , chronic liver disease , platelet count &lt; 100,000 cells/mm3 , WBC &lt; 3,000 cells/mm3 . 10 . Subjects plan elective surgery within first 12 month procedure require discontinue dual antiplatelet therapy 11 . Subject history bleed diathesis coagulatory disease , refuse blood transfusion , significant gastrointestinal urinary bleed within past 12 month . 12 . Subject extensive peripheral vascular disease precludes safe 6F sheath insertion . 13 . Subject history paradoxical exercise induce vasoconstriction consistent myocardial bridging coronary anatomy . 14 . Subjects participate another clinical investigation . 15 . Subjects short life expectancy cancer , Human Immunodeficiency Virus ( HIV ) /Acquired Immune Deficiency Syndrome ( AIDS ) , comorbid condition would limit compliance followup schedule study . Angiographic 1 . Subjects noncandidates PCI . 2 . Any target lesion meet follow criterion : 1 . Aortoostial location ( within 3 mm ) 2 . Lesion locate leave main coronary artery 3 . Lesion locate within 2 mm origin LAD LCx 4 . Lesion involve bifurcation side branch ≥ 2mm diameter ostial lesion &gt; 40 % stenosed visual estimation side branch require intervention 5 . Total occlusion ( TIMI Flow 0 ) , prior wire cross 6 . Extreme tortuosity proximal within lesion 7 . Lesions heavy calcification 8 . Extreme angulation ( ≥ 90 % ) proximal within lesion 3 . Evidence previous revascularization : 1 . Previous PCI without restenosis previous intervention 2 . Arterial venous graft without lesion locate within graft distal diseased arterial saphenous vein graft 4 . The target vessel contain visible thrombus . 5 . Another ( clinically significant potentially significant ) lesion leave untreated within target vessel ( include side branch ) another significant vessel . 6 . Subject require potentially require interventional procedure predilatation study device implantation post dilatation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>MeRes-1 Extend</keyword>
	<keyword>MeRes100</keyword>
	<keyword>Sirolimus Eluting Bioresorbable Vascular Scaffold System</keyword>
</DOC>